Business Context and Reporting Period
This Form 8-K filing by Autonomix Medical, Inc. (AMIX) is dated September 16, 2024. The report addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice.
- Stock Price Deficiency: The closing bid price for common stock remained below $1.00 per share for 30 consecutive business days.
Material Changes
The primary material event is the receipt of a deficiency letter from the Nasdaq Listing Qualifications Department. This notification confirms the company is currently non-compliant with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule) due to the sustained low stock price.
Outlook, Risks, and Management Commentary
Compliance Timeline: The company has been granted an initial 180-day compliance period ending March 17, 2025, to regain compliance. To do so, the stock must close at $1.00 or more for 10 consecutive business days.
Future Options: If compliance is not met by the deadline, the company may be eligible for a second 180-day period, provided it meets other listing standards (excluding bid price) and notifies Nasdaq of its intent to cure the deficiency. This cure may involve a reverse stock split.
Risks:
- Failure to regain compliance could result in delisting from the Nasdaq Capital Market.
- There is no assurance that the company will successfully regain compliance or that an appeal to a NASDAQ Listing Qualifications Panel would be successful if delisting is initiated.
Investor Verification Checklist
- Verify the current closing bid price of AMIX stock to assess proximity to the $1.00 threshold.
- Monitor the company's announcements regarding the potential implementation of a reverse stock split.
- Review the company's cash position in upcoming filings to determine if it has the liquidity to sustain operations while addressing the listing deficiency.
- Check for any subsequent correspondence from Nasdaq regarding the extension of the compliance period or delisting proceedings.